Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0686 in advanced solid tumors
NCT07050459Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0686 in solid tumor (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity, Adverse Events and Serious Adverse Events up to 2 years and 1 more. Started May 2025; status: recruiting.
02
Drugs
SIM0686
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07050459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050459.